The FDA approved Viridian Therapeutics’ thyroid eye disease drug veligrotug, to be marketed as Lumvoa, according to the report. The approval starts a new competitive chapter for the condition, where Amgen’s Tepezza has been the leading blockbuster. With an in-class entrant now cleared, pricing and access discussions are expected to accelerate quickly as payers compare outcomes and safety profiles across both products. The competitive push may also affect how clinicians sequence therapy for patients with thyroid eye disease. For Viridian, the immediate focus shifts to launch execution and post-approval evidence generation that can support broader adoption. For Amgen, the move underscores the risk of market share erosion as the treatment landscape broadens.